Evofem Biosciences Secures 6-Month Extension on Convertible Note Maturity
EVFM sits 29% above its 52-week low of $0.007 on light trading volume (0.1× avg).
Summary
Evofem Biosciences, facing critical liquidity issues, has amended its Securities Purchase Agreement with Adjuvant to extend the maturity date of its convertible promissory notes by six months, providing a temporary reprieve.
Key Events · Financing and Capital Events · EVFM
-
Debt Maturity Extended
Evofem Biosciences entered into a Fourth Amendment to its Securities Purchase Agreement with Adjuvant, extending the maturity date of certain convertible promissory notes.
-
Six-Month Reprieve
The notes are now payable in full on the earliest of six months after April 10, 2026 (October 10, 2026), a change of control, or acceleration.
-
Prepayment Restrictions
The notes may not be prepaid prior to six months after the effective date without the prior written consent of Adjuvant.
-
Addressing Liquidity Concerns
This extension provides a temporary deferral of a significant debt obligation, offering crucial time for a company facing a going concern warning and critical liquidity issues.
Analysis · EVFM · Life Sciences
This amendment is a critical development for Evofem Biosciences, which previously disclosed a going concern warning and critical liquidity issues in its recent 10-K filing. By extending the maturity date of its convertible promissory notes with Adjuvant by six months, the company gains crucial time to address its financial challenges and potentially secure more stable long-term financing. While not a permanent solution, this temporary deferral of a significant debt obligation is a positive step that alleviates immediate pressure and helps avoid a near-term default, which is vital for a company in severe financial distress.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVFM was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $0.01 to $0.02. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.